Save

Positioning of Esketamine Treatment in the Real-world Management of Depression

PHASE4RECRUITING

The goal of this naturalistic, open label, single arm intervention study is to investigate the effects of Esketamine in treating depression. The main aims to answer are: * to investigate whether Esketamine is effective when added to ongoing antidepressant treatment * to identify patient characteristics that will determine a therapeutic response to Esketamine in real-world practice Participants will: * attend the clinic for supervised self-administration of intranasal Esketamine treatment * be observed for 2 hours following Esketamine administration including blood pressure monitoring * be asked to complete a battery of questionnaires * be reimbursed for travel expenses.

Simpliy with AI

Study details:

Depression is a common mental illness, and it is one of the leading causes of disease burden worldwide. Fortunately, there are many effective treatments available for depression, including lifestyle changes, psychological treatments, and medications such as antidepressants. However, not all patients will respond to the first treatment prescribed.

Some patients may only experience a 'partial response', where a few treatments help their depression somewhat, but they do not achieve a full recovery. Currently, the reasons why some patients do not respond, or only experience a partial response to an antidepressant, is not fully understood. Recently, researchers have been investigating new medications that may help patients recover from depression.

One of these new medications is Esketamine, which is a relatively new molecule derived from a drug called Ketamine - an anaesthetic that has been used medically for decades. Researchers have been investigating the antidepressant properties of Ketamine for a long time. It is thought that Ketamine, and its derivative, Esketamine, help to treat depression for a number of reasons.

However, it is not yet known which patients benefit most from Esketamine when used in conjunction with conventional antidepressants. In addition, we do not yet understand how the effect of Esketamine is impacted by other treatments that a patient may be taking for their depression. Finally, it has not yet been investigated how patients with a partial response to an antidepressant will benefit from adding Esketamine to their therapeutic regimen without switching to a new baseline antidepressant.

Therefore, there are two principle aims of this study 1) to investigate whether Esketamine is effective when added to ongoing antidepressant treatment and 2) to identify patient characteristics that will determine a therapeutic response to Esketamine in real-world practice.

Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

Adults aged 18-65 years old

Diagnosis of Major Depressive Disorder (MDD)

Currently depressed

Had an inadequate response to 2 or more courses of antidepressants (of adequate dose and duration)

Be maintained on their current antidepressant medication or psychological therapy at the time of enmrolment

Able to understand and provide informed consent

Exclusion criteria

Concurrent diagnoses: Participants with other 'Diagnostic and Statistical Manual of Mental Disorders' (DSM-5) e.g., current substance misuse disorder, bipolar disorder, schizophrenia; Participants who are unable to understand the study and therefore unable to provide informed consent

Pregnancy: Participants who are pregnant and/or breastfeeding; Participants who are not willing to avoid pregnancy for themselves or their partners during the study by using effective birth control methods

Current medications: Participants taking a total daily dose of benzodiazepines greater than the equivalent of 6mg/day of lorazepam; Participants on complementary and alternative medicine therapies i.e., St John's wort, Chinese medicines, and various herbal and homeopathic treatments

Stimulants: Participants taking stimulants such as methylphenidate, amphetamine, and dextroamphetamine for a diagnosis such as ADHD can still have Esketamine provided they do not continue taking stimulants concurrently for the duration of the study; Concurrent use is excluded due to the synergistic effect with Esketamine that can cause increased blood pressure

Medical history: Participants with current or past history of seizures (uncomplicated childhood febrile seizures with no sequelae are not exclusionary); Participants with a history of uncontrolled hypertension; Participants with uncontrolled diabetes mellitus; Participants with aneurysmal vascular disease including thoracic and abdominal aorta, intracranial and peripheral arterial vessels, or arteriovenous malformation, intracerebral haemorrhage; Participants with untreated glaucoma, current penetrating or perforating eye injury, brain injury, hypertensive encephalopathy, intrathecal therapy with ventricular shunts, or any other condition associated with increased intracranial pressure or increased intraocular pressure or planned eye surgery; Participants who are currently receiving electroconvulsive therapy (ECT) or have received ECT in the past month

Substance Misuse History: Participants who have ever had a substance misuse disorder involving any of the following over their lifetime: ketamine, phencyclidine (PCP), lysergic acid diethylamide (LSD), or 3,4-methylenedioxy-methamphetamine (MDMA), or other hallucinogen use history; Participants with hypersensitivity to Esketamine, Ketamine, or any of the excipients

Simplify with AI

Eligibility

Age eligible for study : 18 and older

Healthy volunteers accepted : No

Gender eligible for study: All

Things to know

Study dates

Study start: 2023-10-31

Primary completion: 2025-09-15

Study completion finish: 2026-01-15

Study type

TREATMENT

Phase

PHASE4

Trial ID

NCT06103760

Intervention or treatment

DRUG: Esketamine Nasal Spray [Spravato]

Conditions

• Major Depressive Disorder

Image related to Major Depressive Disorder

Condition: Major Depressive Disorder
DRUG: Esketamine Nasal Spray [Spravato]
St Leonards, New South Wales, Australia
Sponsor: Royal North Shore Hospital

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial? If you're a clinic or sponsor, you can claim this study. Claim or learn more.

Find a site

Closest Location:

Royal North Shore Hospital

Research sites nearby

Select from list below to view details:

Royal North Shore Hospital
St Leonards, New South Wales, Australia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/Arm	Intervention/Treatment
OTHER: Participants with Major Depressive Disorder Intranasal esketamine to be self-administered by participants under direct supervision of a healthcare professional. First initial dose is 56mg and subsequent doses will be 56mg or 84mg. Esketamine will be administered twice weekly for weeks 1-4, once weekly for weeks 5-8, and once weekly/once fortnightly/once monthly as clinically indicated for weeks 9-25. After each treatment phase, participants will be re-assessed through a comprehensive battery of assessments and dose adjustments will be performed by the study psychiatrist base on tolerability, treatment response, and ongoing consent.	DRUG: Esketamine Nasal Spray [Spravato] This is an uncontrolled, single arm, naturalistic study. There will be three treatment phases: Phase 1 - Acute treatment phase (weeks 1-4); Phase 2 - Maintenance treatment phase (weeks 5-8); Phase 3 - Continuation treatment phase (Weeks 9-25). Phase 1 is the critical component of our study as it determines our primary outcomes.

Participant Group/Arm

Intervention/Treatment

OTHER: Participants with Major Depressive Disorder

Intranasal esketamine to be self-administered by participants under direct supervision of a healthcare professional. First initial dose is 56mg and subsequent doses will be 56mg or 84mg. Esketamine will be administered twice weekly for weeks 1-4, once weekly for weeks 5-8, and once weekly/once fortnightly/once monthly as clinically indicated for weeks 9-25. After each treatment phase, participants will be re-assessed through a comprehensive battery of assessments and dose adjustments will be performed by the study psychiatrist base on tolerability, treatment response, and ongoing consent.

DRUG: Esketamine Nasal Spray [Spravato]

This is an uncontrolled, single arm, naturalistic study. There will be three treatment phases: Phase 1 - Acute treatment phase (weeks 1-4); Phase 2 - Maintenance treatment phase (weeks 5-8); Phase 3 - Continuation treatment phase (Weeks 9-25). Phase 1 is the critical component of our study as it determines our primary outcomes.

What is the study measuring?

Primary outcome

Primary Outcome Measure	Primary Outcome Description	Primary Outcome Time Frame
Percentage of treatment responders determined by a 50% reduction on the Hamilton Depression Rating Scale (HAM-D) 17-Item scoring.	Hamilton Depression Rating Scale (HAM-D) 17-Item scoring	At the end of week 4
Mean depression score on the Quick Inventory of Depressive Symptomatology Self-report (QIDS-SR) 16-Item.	Quick Inventory of Depressive Symptomatology Self-report (QIDS-SR) 16-Item.	Baseline, at the end of weeks 1,2,3, and 4 (primary time point); and further after week 8 and week 12 after Esketamine was commenced.
Global functioning determined by Clinical Global Impression (CGI) score.	Clinical Global Impression (CGI)	Baseline, week 1, week 2, week 3, week 4 (primary time point), week 8 and week 12 after Esketamine was commenced.

Secondary outcome

Secondary Outcome Measure	Secondary Outcome Description	Secondary Outcome Time Frame
Change in mood symptom scores assessed using the visual analogue scale (self-reported)	Visual analogue scale (self-reported)	Baseline, after treatment day 1 and day 3 of each week until Esketamine is ceased.
Depressive symptoms assessed using the Beck Depression Inventory (BDI) 21-Item.	Beck Depression Inventory (BDI) 21-Item.	Baseline and at week 4 after Esketamine was commenced.
Anxiety symptoms assessed using the State-Trait Anxiety Inventory (STAI)	State-Trait Anxiety Inventory (STAI)	Baseline and at week 4 after Esketamine was commenced.

Frequently Asked Questions

Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

No questions submitted. Be the first to ask a question!

You may be eligible to participate in this trial based on your search.Apply for study

Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

References

Clinical Trials Gov: Positioning of Esketamine Treatment in the Real-world Management of Depression